NUK - logo
E-viri
Recenzirano Odprti dostop
  • Precise Gene Editing Preser...
    Schiroli, Giulia; Conti, Anastasia; Ferrari, Samuele; della Volpe, Lucrezia; Jacob, Aurelien; Albano, Luisa; Beretta, Stefano; Calabria, Andrea; Vavassori, Valentina; Gasparini, Patrizia; Salataj, Eralda; Ndiaye-Lobry, Delphine; Brombin, Chiara; Chaumeil, Julie; Montini, Eugenio; Merelli, Ivan; Genovese, Pietro; Naldini, Luigi; Di Micco, Raffaella

    Cell stem cell, 04/2019, Letnik: 24, Številka: 4
    Journal Article

    Precise gene editing in hematopoietic stem and progenitor cells (HSPCs) holds promise for treating genetic diseases. However, responses triggered by programmable nucleases in HSPCs are poorly characterized and may negatively impact HSPC engraftment and long-term repopulation capacity. Here, we induced either one or several DNA double-stranded breaks (DSBs) with optimized zinc-finger and CRISPR/Cas9 nucleases and monitored DNA damage response (DDR) foci induction, cell-cycle progression, and transcriptional responses in HSPC subpopulations, with up to single-cell resolution. p53-mediated DDR pathway activation was the predominant response to even single-nuclease-induced DSBs across all HSPC subtypes analyzed. Excess DSB load and/or adeno-associated virus (AAV)-mediated delivery of DNA repair templates induced cumulative p53 pathway activation, constraining proliferation, yield, and engraftment of edited HSPCs. However, functional impairment was reversible when DDR burden was low and could be overcome by transient p53 inhibition. These findings provide molecular and functional evidence for feasible and seamless gene editing in HSPCs. Display omitted •DNA DSBs induced by programmable nucleases transiently activate the DDR in HSPCs•Single-cell transcriptomics show that induced DSBs activate the p53 pathway•AAV6-mediated genome editing aggravates p53 activation and delays HSPC proliferation•Transient p53 inhibition alleviates clonogenic and repopulation defects in edited HSPCs Precise gene editing has the potential to treat immune and hematological diseases. Genovese, Naldini, Di Micco, and colleagues now show that gene-editing procedures are well tolerated by hematopoietic stem cells and provide molecular evidence of the feasibility of seamless gene editing, strengthening translation of such approaches to humans.